EMAIL THIS PAGE TO A FRIEND

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Systematic review of amifostine for the management of oral mucositis in cancer patients.


PMID 23052919

Abstract

The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients. A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. The body of evidence for the use of amifostine, in each cancer treatment setting was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, or no guideline possible. Thirty papers were reviewed for evidence on amifostine as an intervention for oral mucositis. No guideline was possible for amifostine in any cancer treatment setting due to inadequate and conflicting evidence. Review of the amifostine studies for the prevention and treatment of oral mucositis has found insufficient evidence to support its use in any cancer treatment setting for this purpose. Additional well-designed research is needed to clarify the role of amifostine as an intervention for oral mucositis.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A5922
Amifostine trihydrate, ≥97% (TLC), powder
C5H15N2O3PS · 3 H2O